Grant List
Represents Grant table in the DB
GET /v1/grants?sort=-end_date
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-end_date", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=-end_date", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=2&sort=-end_date", "prev": null }, "data": [ { "type": "Grant", "id": "15530", "attributes": { "award_id": "1R35NS137480-01", "title": "Epitranscriptomic regulation in the mammalian nervous system", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Neurological Disorders and Stroke (NINDS)" ], "program_reference_codes": [], "program_officials": [ { "id": 22867, "first_name": "TIMOTHY M", "last_name": "LAVAUTE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-12-23", "end_date": "2032-11-30", "award_amount": 985026, "principal_investigator": { "id": 12608, "first_name": "Guo-li", "last_name": "Ming", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 232, "ror": "https://ror.org/00b30xv10", "name": "University of Pennsylvania", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 232, "ror": "https://ror.org/00b30xv10", "name": "University of Pennsylvania", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "Epitranscriptomics, analogous to the epigenetic code formed by DNA and histone modifications, is the study of more than 170 chemically distinct types of RNA modifications, which modulate nearly all aspects of RNA metabolism, such as splicing, translocation, decay, stability, and translation. The recent profound success of COVID19 mRNA vaccines utilizing the pseudo-uridine modification highlights the translational potential of epitranscriptomics. Emerging evidence suggests diverse roles and mechanisms of dynamic RNA modifications in the mammalian nervous system and the association of epitranscriptomic dysregulations with developmental, neurological, psychiatric, and degenerative brain disorders. The majority of recent epitranscriptomic studies used cultured immortalized cell lines and the physiological functions of various RNA modifications remain largely unexplored. Recent technical advances in human induced pluripotent stem cell (iPSC)-derived brain organoids and genome editing open doors to investigate epitranscriptomic regulation in human brain development processes and associated brain disorders. The overarching goal of this research program is to investigate roles and mechanisms of epitranscriptomic regulation in the development and function of the mammalian nervous system, and pathological consequences of disrupting these processes, using both mouse and human iPSC-derived 2D and 3D brain organoid models. There are three interrelated projects designed to test innovative hypotheses and generate foundational data for the field. In Project 1, we will focus on the development of the hypothalamus, an understudied brain region that regulates many key physiological functions, such as sleep, reproduction, and feeding, through its distinct nuclei. Based on our preliminary finding of adult-onset obesity of mice with defective m6A signaling, we will test the hypothesis that m6A signaling regulates the fate specification of neural stem cells in the arcuate nucleus for generating feeding-related neurons both in mice and human arcuate organoids. In Project 2, we will use novel sequencing technology to reveal the landscape of locally translated transcripts at synapses and investigate the role of m6A signaling in regulating activity-dependent local translation of these transcripts at synapses in the mouse hippocampus and human hippocampal organoids. In Project 3, we will focus on several risk genes associated with microcephaly that encode writer proteins for diverse epitranscriptomic modifications beyond m6A. We will generate isogenic iPSC lines and genetically modified animal models to test the functional roles and mechanisms of these RNA modifications in cortical neurogenesis. Together, we will use several orthogonal approaches to investigate functional roles and mechanisms of neuroepitranscriptomics in regulating the mammalian nervous system and its causal roles in mediating some forms of developmental pathology. The research program will also provide a platform to train the next generation of scientists from diverse backgrounds at different career stages.", "keywords": [ "3-Dimensional", "Adult", "Animal Model", "Brain", "Brain Diseases", "Brain region", "COVID-19", "Cell Line", "Cell Nucleus", "Chemicals", "Code", "DNA Modification Process", "Data", "Development", "Epigenetic Process", "Genetically Modified Animals", "Goals", "Hippocampus", "Human", "Hypothalamic structure", "Mediating", "Microcephaly", "Modeling", "Modification", "Mus", "Nervous System", "Neurologic", "Neurons", "Obese Mice", "Organoids", "Pathologic", "Pathology", "Physiological", "Process", "Proteins", "Pseudouridine", "RNA", "RNA Splicing", "RNA metabolism", "RNA vaccine", "Regulation", "Reproduction", "Research", "Role", "Scientist", "Signal Transduction", "Sleep", "Specific qualifier value", "Structure of nucleus infundibularis hypothalami", "Synapses", "Testing", "Training", "Transcript", "Translating", "Translations", "career", "cell immortalization", "design", "epitranscriptomics", "feeding", "genome editing", "histone modification", "human induced pluripotent stem cells", "induced pluripotent stem cell", "innovation", "nerve stem cell", "neurogenesis", "next generation", "novel sequencing technology", "programs", "risk variant", "success", "translational potential" ], "approved": true } }, { "type": "Grant", "id": "15531", "attributes": { "award_id": "1R35NS137447-01", "title": "Expanding insights into FTD disease mechanisms", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Neurological Disorders and Stroke (NINDS)" ], "program_reference_codes": [], "program_officials": [ { "id": 23658, "first_name": "FRANK PAUL", "last_name": "Shewmaker", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-12-15", "end_date": "2032-11-30", "award_amount": 1138538, "principal_investigator": { "id": 20546, "first_name": "LEONARD", "last_name": "PETRUCELLI", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1414, "ror": "", "name": "MAYO CLINIC JACKSONVILLE", "address": "", "city": "", "state": "FL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1414, "ror": "", "name": "MAYO CLINIC JACKSONVILLE", "address": "", "city": "", "state": "FL", "zip": "", "country": "United States", "approved": true }, "abstract": "Frontotemporal lobar degeneration (FTLD), which underlies frontotemporal dementia (FTD), encompasses a group of disorders with significant genetic, clinical, and neuropathological heterogeneity. FTLD is also genetically and pathologically associated with the motor neuron disease amyotrophic lateral sclerosis (ALS), with some patients developing both disorders. Understanding the diverse mechanisms governing FTLD pathogenesis is a fundamental area of interest of my research program, and we pursue this goal by asking impactful questions and applying innovative techniques. To accelerate scientific discovery, we have adopted a comprehensive approach that investigates multiple FTLD mechanisms driven by key molecular players like C9orf72, TDP-43, progranulin, tau and, more recently, TMEM106B. We also place great emphasis on translational research geared towards identifying much needed biomarkers and therapies, an area of particular importance given that there exists no treatment for FTLD. Since the funding of my current R35 at the end of 2016, my group has uncovered seminal findings related to the pathomechanisms mediated by FTLD-associated mutations in C9orf72 and GRN and shed crucial insight into the consequences of pathogenic TDP-43 and tau deposition in the brain. These findings have garnered high-impact publications in Science, Nature, and Cell and inspired new and ongoing avenues of research in my lab. The flexibility afforded by the R35 funding opportunity also allowed us to branch into other related topics and tackle urgent issues in the broader neuroscience field, including the need for biomarkers and mouse models for distinct repeat-associated disorders like spinocerebellar ataxias and the recent pressing need for tools to study and understand COVID-19 and its impact on the brain. Our productivity is influenced by the excellent research environment fostered at Mayo Clinic, which brings together highly interactive and devoted neurobiologists, geneticists, neuropathologists and physician scientists, the diversity of my team, and the numerous collaborations we have forged with world-renowned experts in the field, as well as our dedication to stewardship and the sharing of information and resources with the scientific community at large. Drawing from our past work on FTLD, we now propose to explore current cutting-edge questions related to: (1) the molecular underpinnings of TDP-43 localization and function and the downstream consequences of its dysfunction in disease, (2) the mechanisms underlying cryptic splicing in TDP-43 proteinopathies and the role of cryptic RNA and proteins in FTLD, (3) the role of the endo-lysosomal system in the development of TDP-43 pathology and neurodegeneration, and (4) the emerging role of TMEM106B fibrillogenesis in diverse neurodegenerative diseases including TDP-43 proteinopathies and tauopathies. We will use a combination of mouse and induced pluripotent stem-cell modeling, transcriptomics, proteomics, histology, and human tissue analyses to carry-out our proposed studies and address new and potentially transformative ideas as they emerge.", "keywords": [ "Acceleration", "Address", "Adopted", "Affect", "Amyotrophic Lateral Sclerosis", "Area", "Behavior", "Biological Markers", "Brain", "C9ORF72", "COVID-19", "Cells", "Clinic", "Clinical", "Collaborations", "Communities", "Dedications", "Deposition", "Development", "Disease", "Disease Progression", "Environment", "Fostering", "Frontotemporal Dementia", "Frontotemporal Lobar Degenerations", "Functional disorder", "Funding", "Funding Opportunities", "Genetic", "Goals", "Heterogeneity", "Histology", "Language", "Mediating", "Molecular", "Monitor", "Motor Neuron Disease", "Mus", "Mutation", "Nature", "Nerve Degeneration", "Neurodegenerative Disorders", "Neurosciences", "PGRN gene", "Pathogenesis", "Pathogenicity", "Pathologic", "Pathology", "Patients", "Personality", "Physicians", "Process", "Productivity", "Proteins", "Proteomics", "Publications", "RNA", "RNA Splicing", "Research", "Resources", "Role", "Science", "Scientist", "Seminal", "Spinocerebellar Ataxias", "System", "Tauopathies", "Techniques", "Translational Research", "Work", "fibrillogenesis", "flexibility", "forging", "human tissue", "improved", "induced pluripotent stem cell", "innovation", "insight", "interest", "mouse model", "neuropathology", "novel", "patient prognosis", "prevent", "programs", "protein TDP-43", "stem cell model", "tau Proteins", "tool", "transcriptomics" ], "approved": true } }, { "type": "Grant", "id": "15401", "attributes": { "award_id": "1UM1TR004906-01", "title": "Center for Clinical and Translational Sciences", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [ { "id": 12440, "first_name": "CAROL", "last_name": "MERCHANT", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-07-24", "end_date": "2031-06-30", "award_amount": 5707763, "principal_investigator": { "id": 24633, "first_name": "Maria Eulalia", "last_name": "Fernandez", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 788, "ror": "", "name": "UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 12442, "first_name": "David D", "last_name": "McPherson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 24637, "first_name": "Belinda", "last_name": "Reininger", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 32000, "first_name": "LORNA H.", "last_name": "MCNEILL", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 32001, "first_name": "FUNDA", "last_name": "MERIC-BERNSTAM", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 32002, "first_name": "JIAJIE", "last_name": "ZHANG", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 788, "ror": "", "name": "UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "PROJECT SUMMARY/ ABSTRACT Since its inception in 2006, our CCTS has assembled a well-integrated, and high-impact network in Texas including 6 academic institutions: The University of Texas Health Science Center at Houston (UTH-H), the University of Texas M.D. Anderson Cancer Center (MDACC), Rice University, University of Texas at Tyler (UT- Tyler), University of Texas Rio Grande Valley (UT-RGV), and two UTH-H affiliated hospital systems (Memorial Hermann and Lyndon B. Johnson County Hospital). We have actively supported and integrated our partners into NCATS national initiatives, including recent recruitment of a large number of diverse patients for COVID-19 trials and studies. Over the past 17 years, our CCTS has supported investigators at 30 institutions from over 97 biomedical fields who disseminate scientific and healthcare initiatives that impact diverse populations. By expanding our network to include Texas Tech University Health Sciences Center El Paso (TT-EP), our catchment now encompasses ~23,000 sq. miles and over 16 million residents (4% of the U.S. population) showing some of the greatest diversity in the country. Each partner institution brings communities with unique geographic, demographic, cultural and socio-economic characteristics and challenges. In the next cycle, we will thoroughly integrate translational science into our entire program and expedite the output of scientific observations policies discoveries, clinical and community experiences into effective treatments, clinical interventions and public health that improve the health of people within our diverse state and beyond.Our shared leadership model and partnerships across the disparate regions of Texas will enable us to carry out our 6 strategic goals: (1) Enhance our robust organizational structure of Cores to improve and expand the impact of CCTS programs on translational science (Element B); (2) Promote partnerships and collaborations of stakeholders that extend benefits of translational science to underserved populations (Element B & Module C2); (3) Enhance integration of D&I sciences across our CTSA (Module C2); (4) Innovate scientific and operational functions of CRUs to expand the effectiveness and accessibility of CTS in broadly heterogeneous populations (Module D1); (5) Foster education and career training in translational science by establishing methods that inspire our growing workforce of clinical research professionals (Modules C1 & D2); (6) Create and disseminate innovative Health Informatics (HI) solutions to become a national resource for the response to urgent public health needs of underserved populations (Module D3). To accomplish these strategic goals, we will pursue our 3C's and 5I's motto: Community, Collaboration & Careers (3C's) and Impact, Inclusion, Implementation, Innovation, & Informatics (5I's). Our leadership and organizational model, resources, partnerships, and research infrastructure have been strategically planned so diagnosis, goal that more people get the benefits of translational science, from access to accurate efficacious treatment to cost-effective disease prevention strategies. This is our mission and our major which reflectsNCATS's vision: a world with “more treatments for ALL people more quickly”.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15386", "attributes": { "award_id": "1UM1TR004772-01", "title": "Dartmouth Clinical and Translational Science Institute", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [ { "id": 21567, "first_name": "Jamie Mihoko", "last_name": "Doyle", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-07-25", "end_date": "2031-06-30", "award_amount": 4073191, "principal_investigator": { "id": 31986, "first_name": "Steven L", "last_name": "Bernstein", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 31987, "first_name": "KEITH D.", "last_name": "PAULSEN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 31988, "first_name": "Anna N. A.", "last_name": "Tosteson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 2072, "ror": "", "name": "DARTMOUTH-HITCHCOCK CLINIC", "address": "", "city": "", "state": "NH", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 pandemic brought into stark relief the many healthcare challenges facing individuals living in rural areas—the compounded needs of an aging population, geographic dispersion, inadequate public transportation, spotty internet service, spikes in substance use, vaccine hesitancy. These disparities—like most public health problems—reflect a complex interplay of biological, environmental, psychological, social, and systems-level factors. At the same time, the pandemic highlighted potential solutions and spurred a wealth of research in healthcare delivery science in rural areas. Much of this work was conducted by scientists affiliated with SYNERGY, Dartmouth’s Clinical and Translational Science Institute, founded in 2013. SYNERGY faculty reported the expanded use of telehealth, digital health, machine learning; strengthened partnerships between healthcare systems and community health centers; and developed a “COVID compass” to guide policymaking. Our work in this area, centered in SYNERGY’s earliest years, has deepened our commitment to translational science that centers rural healthcare delivery and health equity, while exploring the full spectrum of translational science and workforce development. Hence, we propose to return SYNERGY to the national CTSA consortium. The overarching goal of this application is to continue to spur innovation in clinical and translational science with a focus on rural healthcare, in collaboration with other CTSA hubs, and to study a new model to catalyze T3 translational science in healthcare settings. SYNERGY reflects a close partnership between Dartmouth Health (DH) and Dartmouth College (DC). DH is the largest healthcare system in New Hampshire, with its flagship hospital in a rurally designated area. DC brings the resources of a research- intensive college, including schools of medicine, engineering, business, and graduate studies. SYNERGY includes our new Center for Rural Healthcare Delivery Science and key regional collaborators, including the Northern New England Clinical Translational Research Network (a partnership between MaineHealth and the University of Vermont), a Veterans Affairs hospital, community groups, and a “pipeline” program to grow the scientific workforce. SYNERGY’s goals are to (1) Accelerate the delivery of evidence-based diagnostics, therapeutics, and processes to address the healthcare needs of rural communities; (2) Assure the availability of timely, actionable patient- and population-level data to mitigate the translational block of “siloing” between translational scientists and healthcare system leadership by deploying a novel coproduction learning health system (LHS); (3) Train the next generation of translational scientists, with a particular focus on identifying future leaders in healthcare delivery science and rural health; (4) Disseminate these practices and lessons learned within the CTSA community through engagement with subnetworks addressing rural health, implementation science, and learning health systems science; and (5) Involve local communities in the design, conduct, analysis, and dissemination of our work, while engaging in studies of stakeholder engagement.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "14592", "attributes": { "award_id": "1UM1TR004771-01", "title": "CTSA UM1 at the University of Alabama at Birmingham", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [ { "id": 21618, "first_name": "Audie A", "last_name": "Atienza", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-05-01", "end_date": "2031-04-30", "award_amount": 9869052, "principal_investigator": { "id": 31258, "first_name": "PATRICE", "last_name": "DELAFONTAINE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 11466, "first_name": "Robert P.", "last_name": "Kimberly", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 612, "ror": "https://ror.org/008s83205", "name": "University of Alabama at Birmingham", "address": "", "city": "", "state": "AL", "zip": "", "country": "United States", "approved": true } ] }, { "id": 31259, "first_name": "Orlando M", "last_name": "Gutierrez", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 612, "ror": "https://ror.org/008s83205", "name": "University of Alabama at Birmingham", "address": "", "city": "", "state": "AL", "zip": "", "country": "United States", "approved": true }, "abstract": "– The Center for Clinical and Translational Science (CCTS), the CTSA Hub at the University of Alabama at Birmingham (UAB), serves a region of the country with a disproportionate burden of multiple chronic diseases and health disparities. The COVID-19 pandemic brought into sharp relief the critical importance of translating new scientific discoveries into interventions that improve the health of patients and their communities in an efficient, effective and equitable manner. The unique health challenges faced by our communities previously prompted the creation of the CCTS Partner Network – spanning Alabama, Mississippi and Louisiana – to ensure that our research and training efforts serve the populations in our region while maximizing collaborative synergies in clinical and translational science (CTS) investigation to catalyze discovery and accelerate the dissemination and implementation of evidence toward health impact. As it continues to serve as a national resource for responding to public health emergencies, the CCTS Partner Network will provide programmatic leadership and shared governance (Aim 1) to mobilize the resources and talents throughout the region as it brings together academic, health system, industry and community partners to advance discovery science in concert with the CTSA consortium. The CCTS will further the development of a vibrant, diverse clinical and translational research workforce (Aim 2) by expanding programs that provide both didactic and experiential training to convey new skills, perspectives and understanding of the translation process for faculty, trainees, clinical research professionals and community alike. The Center will promote community and stakeholder engagement (Aim 3) in trusting, bidirectional relationships in all aspects of the research process to develop, demonstrate, disseminate and implement new discoveries to enhance the impact of health insights on those who will most benefit. It will leverage expertise in health informatics, clinical research informatics and translational bioinformatics to extend collaborative, coordinated data analytics and digital innovations across the Partner Network and the CTSA consortium (Aim 4) that allow full utilization of real world data together with rich, deep clinical information to enable discovery research from the bench to the learning healthcare system. The CCTS Hub and Network will support ethical, scientifically rigorous, informative clinical trials and pilot studies by providing a range of specialized services, resources and consultations (Aim 5) guided by NCATS principles of effective translational science. Through these efforts, the CCTS will formalize its CTS Research Program (Aim 6) to identify, develop and test novel approaches to overcome significant roadblocks in biomedical research, generating new insights that can be generalized to other CTSA Hubs. By achieving these aims, the CCTS will harness the Network’s vibrant collaborative energy to accelerate the discovery, dissemination and implementation of new findings, deliver treatments to more people more quickly, reduce the burden of chronic disease and advance health equity in the Deep South and beyond.", "keywords": [ "Acceleration", "Address", "Affect", "Alabama", "Area", "Back", "Bioinformatics", "Biomedical Research", "Biotechnology", "COVID-19 pandemic", "Chronic Disease", "Clinical", "Clinical Research", "Clinical Sciences", "Clinical Trials", "Communication", "Communities", "Complement", "Consultations", "Country", "Data", "Data Analytics", "Dedications", "Deep South", "Development", "Disease", "Disparity", "Dissemination and Implementation", "Diverse Workforce", "Ecosystem", "Ensure", "Equity", "Ethics", "Evaluation", "Faculty", "Feedback", "Future", "Goals", "Growth", "Health", "Health Sciences", "Health system", "Healthcare Systems", "Informatics", "Infrastructure", "Institution", "Intervention", "Investigation", "Knowledge", "Leadership", "Learning", "Louisiana", "Malignant Neoplasms", "Medical center", "Mentors", "Mission", "Mississippi", "National Center for Advancing Translational Sciences", "Neurologic", "Patients", "Persons", "Pilot Projects", "Population", "Process", "Public Health", "Public Health Informatics", "Research", "Research Methodology", "Research Project Grants", "Research Support", "Resource Informatics", "Resources", "Science", "Scientific Advances and Accomplishments", "Services", "Special needs", "Talents", "Testing", "Training", "Training Programs", "Training and Education", "Translating", "Translation Process", "Translational Research", "Trust", "Universities", "Vision", "Work", "burden of chronic illness", "cardiometabolism", "career", "clinical center", "community partners", "community partnership", "data interoperability", "design", "digital", "disease disparity", "evidence base", "health care delivery", "health disparity", "health equity", "high dimensionality", "improved", "industry partner", "innovation", "insight", "multidisciplinary", "novel strategies", "novel therapeutics", "programs", "public health emergency", "research study", "skills", "synergism", "tool" ], "approved": true } }, { "type": "Grant", "id": "15953", "attributes": { "award_id": "1K08AI196260-01", "title": "Human upper airway immune memory kinetics and durability against respiratory pathogens", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32599, "first_name": "MICHELLE MARIE", "last_name": "ARNOLD", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-04-02", "end_date": "2031-03-31", "award_amount": 159300, "principal_investigator": { "id": 44398, "first_name": "Sydney Ilima", "last_name": "Ramirez", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3411, "ror": "", "name": "LA JOLLA INSTITUTE FOR IMMUNOLOGY", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Peripheral blood is the primary sample type collected to evaluate a vast range of medical conditions. However, peripheral blood testing may not reflect processes occurring in tissue, like the upper airway. The SARS- CoV-2 (SARS2) pandemic highlighted the importance of being able to sample the upper airway for purposes including evaluation of viral infection and clearance. Although the upper airway represents the primary site of infection for many human pathogens, critical questions remain regarding upper airway immunity and protection. Nasal cavity swab sampling can be used to bridge knowledge gaps regarding upper airway immunity to important respiratory pathogens like SARS2 and to address important immunologic questions where peripheral blood sampling is inherently insufficient. I established novel methods for reproducible, longitudinal sampling of upper airway immune cell populations using swabs and demonstrated that sufficient numbers of viable immune cells could be collected to allow for high resolution downstream analyses, including multiparametric flow cytometry and single cell RNA sequencing. Upper airway resident memory B and T cell populations, including SARS2- specific memory B and T cells were characterized using these methods. There is great interest in developing next generation vaccines, including vaccines that can elicit robust mucosal immune responses. This requires knowledge of the immunologic contexts in which mucosal immunity is generated and the requirements for maintenance of upper airway immune memory. I hypothesize that local antigen exposure is required to develop durable upper airway immune memory, and intramuscular immunization alone may fail to elicit upper airway immunity despite generating circulating immunity. I will test this hypothesis by studying upper airway memory B and T cell frequencies, diversity, kinetics and durability in distinct immunologic contexts including SARS2 breakthrough infection (BTI) and COVID-19 booster vaccination using this award. Other respiratory pathogens of public health importance will also be examined. If funded, this K08 will assist with my transition to becoming a successful independent physician scientist investigator in human immunology and infectious diseases. The La Jolla Institute for Immunology (LJI) is a superb training environment and located on the campus of another excellent academic research and medical institution, the University of California, San Diego (UCSD). I will receive ongoing mentorship from an established investigator with a track record for producing successful mentees, Professor Shane Crotty, PhD, a world- renowned expert in the field of immunology. LJI and UCSD are closely affiliated, and Dr. Crotty has an adjunct appointment at UCSD. I will have access to resources at both LJI and UCSD for this career development award. As an Associate Physician in UCSD’s Division of Infectious Diseases I will receive additional mentorship in academic career development, and maintain my clinical acumen by providing part-time medical care and consultation services for medically complex patients.", "keywords": [ "2019-nCoV", "Address", "Adult", "Animal Model", "Antibodies", "Antibody Response", "Antibody titer measurement", "Antigens", "Appointment", "Award", "B-Lymphocytes", "Blood Tests", "Blood specimen", "CD8-Positive T-Lymphocytes", "COVID-19 booster", "COVID-19 pandemic", "COVID-19 vaccination", "California", "Caring", "Cell Survival", "Cell secretion", "Cells", "Clinical", "Common Cold", "Communicable Diseases", "Complex", "Consultations", "Coronavirus", "Coronavirus Infections", "Data", "Development", "Disease", "Doctor of Philosophy", "Enrollment", "Environment", "Epitopes", "Evaluation", "Flow Cytometry", "FluMist", "Frequencies", "Funding", "Human", "Immune", "Immunity", "Immunization", "Immunoglobulin A", "Immunologic Memory", "Immunologics", "Immunology", "Immunophenotyping", "Infection", "Infection Control", "Infection prevention", "Influenza", "Institution", "Intramuscular", "Investigation", "K-Series Research Career Programs", "Kinetics", "Knowledge", "Left", "Licensing", "Maintenance", "Mediating", "Medical", "Memory", "Memory B-Lymphocyte", "Mentorship", "Methods", "Morbidity", "Mucosal Immune Responses", "Mucosal Immunity", "Mucous Membrane", "Nasal cavity", "Nasal turbinate bone structure", "Nasopharynx", "Nose", "Patients", "Physicians", "Play", "Population", "Primates", "Process", "Public Health", "Reproducibility", "Research", "Research Personnel", "Resolution", "Resources", "Role", "SARS-CoV-2 exposure", "SARS-CoV-2 immunity", "SARS-CoV-2 infection", "SARS-CoV-2 variant", "Sampling", "Scientist", "Secondary Immunization", "Services", "Severity of illness", "Site", "Source", "Swab", "T cell response", "T-Cell Receptor", "T-Lymphocyte", "Testing", "Time", "Tissues", "Training", "Universities", "Vaccination", "Vaccine Design", "Vaccines", "Viral", "Virus Diseases", "acquired immunity", "adaptive immunity", "breakthrough infection", "career development", "cohort", "cross reactivity", "cytokine", "experimental study", "flu", "human pathogen", "influenza virus vaccine", "insight", "interest", "live attenuated influenza vaccine", "minimally invasive", "mortality", "mucosal vaccine", "nasopharyngeal swab", "neutralizing antibody", "novel", "novel strategies", "novel therapeutics", "novel vaccines", "pandemic disease", "peripheral blood", "professor", "respiratory pathogen", "respiratory virus", "response", "severe COVID-19", "single-cell RNA sequencing" ], "approved": true } }, { "type": "Grant", "id": "15946", "attributes": { "award_id": "1R01AI196117-01", "title": "Advancing Analytical Tools to Quantify and Mitigate the Risk for Transitioning from Episodic to Endemic Transmission for Emerging Infections", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32873, "first_name": "MISRAK", "last_name": "GEZMU", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-04-10", "end_date": "2031-03-31", "award_amount": 787837, "principal_investigator": { "id": 26281, "first_name": "Seth", "last_name": "Blumberg", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3405, "ror": "", "name": "UNIVERSITY OF CALIFORNIA, SAN FRANCISCO", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "This project will develop and apply computational tools for assessing the risk that diseases with episodic transmission become established in the general population. Our project is relevant to emerging zoonoses, re-emerging vaccine-preventable diseases, and healthcare-associated infections. Timely identification and control of such diseases could have significantly altered the course of mpox, SARS-CoV-2, and antimicrobial resistance. It is therefore important to have methods available to monitor and fully elucidate the transmission patterns of infectious diseases that can develop increased burden through pathogen evolution, reduced population immunity, or other sociodemographic changes. Any such method needs to consider patchy surveillance and differences in risk among those who are exposed to the disease. Furthermore, diseases that cause episodic outbreaks might require specific control strategies that are different from those that apply to epidemic or endemic diseases. Existing models that explore some of these aspects typically omit key factors, rely on untested assumptions, or are validated in a circular fashion using simulations based on the same assumptions they aim to test. This limits their reliability for real-world applications. To address this gap, we will combine statistical inference with simulation approaches to address key questions in quantifying and mitigating the risk from infectious diseases. We will extend methods for inference using branching process models to take into account imperfect observations and heterogeneity in both transmission and susceptibility. We will apply these methods to a range of applications to improve our ability to learn from data describing sporadic infection clusters. We will also use mobility and demographic data to construct synthetic populations representing situations where infections cause occasional outbreaks. This will permit stress-testing of inference methods and evaluation of control strategies. Our iterative approach will allow us to refine model assumptions, improve inference robustness, and identify the most informative data types for public health surveillance and control. The work will result in a greater understanding of how public health agencies can best use data from episodic disease transmission and computational tools for applying this understanding to coming threats. To demonstrate the breadth of applicability, we will apply our methodological advancements to (1) quantify the transmissibility of H5N1 influenza, (2) determine the probability of large measles outbreaks occurring annually, and (3) evaluate control strategies for reducing transmission of virulent, healthcare-associated MRSA strains. To promote scientific reproducibility, we will produce user-friendly software that integrates with existing packages and share synthetic population data. Our team is well-positioned to conduct this work since we have developed many existing tools and paradigms for analyzing episodic transmission, including branching process models and outbreak simulations in synthetic populations. By advancing the science of disease transmission and equipping public health agencies with actionable results, this work will reduce the risk of future pandemics.", "keywords": [ "2019-nCoV", "Address", "Antimicrobial Resistance", "Behavior", "COVID-19 pandemic", "California", "Cations", "Clinical Data", "Communicable Diseases", "Communities", "County", "Data", "Data Collection", "Disease", "Disease Outbreaks", "Effectiveness", "Emerging Communicable Diseases", "Emerging infection", "Endemic Diseases", "Epidemic", "Epidemiology", "Evaluation", "Evolution", "Exhibits", "Exposure to", "Future", "General Population", "Goals", "Health Care", "Heterogeneity", "Household", "Human", "Immunity", "Individual", "Infection", "Influenza", "Influenza A Virus H5N1 Subtype", "Intervention", "Learning", "Link", "Measles", "Methodology", "Methods", "Modeling", "Modernization", "Monitor", "Monkeypox", "Pattern", "Population", "Population Surveillance", "Positioning Attribute", "Predisposition", "Probability", "Process", "Public Health", "Reproducibility", "Reproduction", "Research", "Resources", "Risk", "Risk Assessment", "Risk Reduction", "Route", "Science", "Statistical Methods", "Stress Tests", "Structure", "Study models", "Techniques", "Testing", "United States", "Vaccines", "Virulent", "Work", "Zoonoses", "advanced analytics", "analytical tool", "computerized tools", "data streams", "disease transmission", "disorder control", "disorder risk", "evidence base", "future pandemic", "generative artificial intelligence", "health care associated infections", "improved", "innovation", "mathematical model", "methicillin resistant Staphylococcus aureus", "model development", "models and simulation", "novel", "pathogen", "predicting response", "prevent", "previous pandemic", "public health intervention", "real world application", "risk mitigation", "simulation", "sociodemographics", "synthetic construct", "tool", "transmission process", "user friendly software" ], "approved": true } }, { "type": "Grant", "id": "15944", "attributes": { "award_id": "1R01AI195454-01", "title": "Hijacking the neonatal Fc receptor: the novel biology of arterivirus entry, transmission, and persistence", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 44307, "first_name": "RODOLFO M", "last_name": "ALARCON", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-04-03", "end_date": "2031-03-31", "award_amount": 615446, "principal_investigator": { "id": 31459, "first_name": "Adam Lee", "last_name": "Bailey", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3403, "ror": "", "name": "UNIVERSITY OF WISCONSIN-MADISON", "address": "", "city": "", "state": "WI", "zip": "", "country": "United States", "approved": true }, "abstract": "Understanding novel mechanisms by which animal viruses enter cells, evade immunity, and cause disease has scientific and public health importance. Arteriviruses are an understudied family of RNA viruses (related to coronaviruses) that infect a wide variety of mammals. The host and viral factors that determine arterivirus disease, persistence, and cross-species transmission remain unknown and unpredictable. This lack of understanding has implications for predicting/thwarting arterivirus emergence in humans, as some arteriviruses have been shown to infect human cells. Macrophages are exclusively infected by most arteriviruses, but the subpopulation(s) of macrophages that support arterivirus replication remain poorly defined. The process by which arteriviruses enter cells is highly novel and also poorly understood. Each virion displays an unusually large set of surface glycoproteins (7-11 depending on the virus) that are unlike any known viral fusion machinery. The macrophage-specific molecule CD163 is a required arterivirus receptor, yet CD163 by itself is insufficient to mediate arterivirus entry. We recently identified the neonatal Fc receptor (FcRn) as an important entry factor that arteriviruses use together with CD163 to gain entry into cells. Aim 1 of this project builds upon this discovery to define the molecular details of the arterivirus:FcRn interaction. In Aim 1a, we will map the site(s) on FcRn that are critical for arterivirus engagement by creating chimeric FcRn molecules that incorporate features of arterivirus-permissive and -resistant FcRn orthologs, with the goal of defining the domains, motifs, and residues involved in arterivirus/FcRn interactions. In Aim 1b, we will generate chimeric arteriviruses that contain combinations of glycoproteins from different arteriviruses, seeking to define the viral glycoproteins, domains, motifs, and residues involved in FcRn engagement. In Aim 1c, we will continue to develop our understanding of the host factors required for arterivirus entry by performing screens to identify additional host factors that are functionally redundant with FcRn for the viral entry process. In Aim 2, we will use the murine arterivirus (lactate dehydrogenase-elevating virus, LDV), which causes life-long viremia in adult mice, to understand several aspects of arterivirus infection in vivo. In Aim 2a, we will use a nanoluciferase-expressing LDV to perform body-wide imaging and identify the tissues that support LDV infection over time. In Aim 2b, we will hone in key tissues and identify the macrophage populations within these tissues that support LDV infection and determine how persistent arterivirus infection impacts recovery of target cell populations. Finally, in Aim 2c we will use FcRn-knockout mice to determine whether arteriviruses hijack FcRn’s physiologic role in placental biology, potentially explaining the high efficiency with which arteriviruses transmit vertically. This project will provide insights into novel mechanisms of viral entry, macrophage infection and dysfunction, viral persistence, and vertical transmission through the study of the neglected “pre-emergent” family of mammalian viruses, the arteriviruses.", "keywords": [ "Acute", "Acute Disease", "Adult", "Anatomy", "Animals", "Arterivirus", "Arterivirus Infections", "Biology", "Cell Culture Techniques", "Cell Line", "Cell Surface Receptors", "Cells", "Clustered Regularly Interspaced Short Palindromic Repeats", "Complex", "Coronavirus", "Development", "Disease", "Distant", "Family", "Family suidae", "Farm", "Fc Receptor", "Fetus", "Functional disorder", "Glycoproteins", "Goals", "Human", "Image", "Immune system", "Immunity", "Immunoglobulin G", "Industry", "Infection", "Integration Host Factors", "Knock-out", "Knockout Mice", "Knowledge", "Laboratories", "Lactate dehydrogenase-elevating virus", "Life Cycle Stages", "Link", "Macrophage", "Mammals", "Maps", "Mediating", "Membrane Glycoproteins", "Modeling", "Molecular", "Mus", "Orthologous Gene", "Phase", "Physiological", "Placenta", "Placental Biology", "Pneumonia", "Population", "Positioning Attribute", "Predisposition", "Primates", "Process", "Public Health", "RNA Viruses", "Recovery", "Reporter", "Research", "Resistance", "Retinal blind spot", "Role", "Site", "Structure", "Surface", "Syncytiotrophoblast", "System", "Time", "Tissues", "Tropism", "Vertical Transmission", "Viral", "Viral Hemorrhagic Fevers", "Viremia", "Virion", "Virus", "Virus Receptors", "Virus Replication", "Whole Organism", "cell immortalization", "chronic infection", "cross-species transmission", "economic impact", "fetal", "genome-wide", "in utero", "in vivo", "insight", "medical countermeasure", "model organism", "nanoluciferase", "neglect", "neonatal Fc receptor", "novel", "permissiveness", "pregnant", "receptor", "reverse genetics", "time use", "transmission process" ], "approved": true } }, { "type": "Grant", "id": "15950", "attributes": { "award_id": "1K08AI196255-01", "title": "Neutralizing antibody pressure on the evolution of SARS-CoV-2 variants.\"", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32891, "first_name": "MARY KATHERINE BRADFORD", "last_name": "PLIMACK", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-04-02", "end_date": "2031-03-31", "award_amount": 194160, "principal_investigator": { "id": 44394, "first_name": "Ian Alexander", "last_name": "Mellis", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3409, "ror": "", "name": "COLUMBIA UNIVERSITY HEALTH SCIENCES", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "/ ABSTRACT: Rationale: SARS-CoV-2 evolution has led to the emergence of viral variants that evade existing immunity in the human population, which continue to pose a threat to global public health. It has proven challenging to predict which mutations will arise in future dominant viral variants, and, as a result, it is difficult to design vaccines that provide adequate protection against viruses that will circulate in future waves of infections. Our preliminary data show that viral variant evolution is most closely correlated with evasion of serum neutralizing antibodies, and that serum neutralizing antibody responses are shaped by immune imprinting to the ancestral D614G strain. This mentored career project aims to leverage these observations to develop an in vitro model for predicting where mutations will appear in the virus and to use that information to design updated vaccines. Candidate: As a Transfusion Medicine fellow with a PhD in Genomics and Computational Biology and two years of experience in virology and immunology research, I bring a unique complement of perspectives and skills to the analysis of viral and antigenic evolution and to vaccine design strategies. Further training in advanced BSL-2-compatible pseudovirus culture, mouse immunization, and computational structural biology will be central to the completion of the proposed project and to my development as an independent physician-scientist aiming to improve our understanding and mitigation of pathogen evolution. My primary mentor, Dr. David Ho, an international leader in virology, and my complementary multidisciplinary advisory team, will ensure my research and career development progress. Environment: The Ho laboratory at the Columbia University Irving Medical Center (CUIMC) is a world leader in the study of pandemic viruses, including SARS-CoV-2, with expertise in the characterization of viral variants and serum antibody analysis. The Ho lab has access to abundant resources and many collaborators, including leaders in pseudovirus construction, structural biology, and vaccine design. CUIMC also has a long track record of supporting junior physician-scientists on their paths to successful independent careers in academic medicine. Approach: We will test the central hypothesis that widespread early exposure to ancestral SARS-CoV-2 shapes the evolutionary trajectory of the virus and that such a trajectory can be modeled in vitro. In Aim 1 we will assess the impact of mouse serum neutralizing antibodies elicited by different immunization histories on mutational profiles in cultured BSL-2-rated pseudoviruses and correlate mutations with historical public health databases. In Aim 2, we will identify whether particular epitopes on the spike protein are particularly susceptible to the emergence of mutations under serum antibody selective pressure. In Aim 3, we will design and test novel COVID-19 vaccine candidates in mice based on observed mutations that arise in pseudoviruses. This project will enhance our understanding of SARS-CoV-2, provide a framework for in vitro modeling of antigenically variable pathogens, and contribute to vaccine design strategies.", "keywords": [ "2019-nCoV", "Advisory Committees", "Antibodies", "Antibody Response", "Antigenic Variation", "Antigens", "Biological Assay", "COVID-19", "COVID-19 booster", "COVID-19 vaccine", "Cessation of life", "Complement", "Computational Biology", "Data", "Databases", "Dengue", "Development", "Doctor of Philosophy", "Ensure", "Environment", "Epitopes", "Escape Mutant", "Evolution", "Exposure to", "Formulation", "Frequencies", "Future", "Genomics", "Growth", "Human", "Immune", "Immune response", "Immunity", "Immunization", "Immunize", "Immunology", "Impairment", "In Vitro", "Individual", "Infection", "Influenza", "International", "Junior Physician", "Laboratories", "Machine Learning", "Maps", "Measures", "Medical center", "Medicine", "Mentors", "Modeling", "Monoclonal Antibodies", "Mus", "Mutation", "Physicians", "Population", "Predisposition", "Proteins", "Public Health", "RNA vaccine", "Recording of previous events", "Research", "Resolution", "Resources", "SARS-CoV-2 spike protein", "SARS-CoV-2 variant", "Scientist", "Serum", "Shapes", "Structural Models", "System", "Testing", "Training", "Universities", "Update", "Vaccination", "Vaccine Design", "Vaccines", "Variant", "Vesicular stomatitis Indiana virus", "Viral", "Viral Genome", "Virus", "Work", "booster vaccine", "candidate identification", "career", "career development", "cohort", "design", "emerging virus", "experience", "exposure mixture", "genome sequencing", "imprint", "improved", "in vitro Model", "innovation", "multidisciplinary", "mutant", "mutation screening", "neutralizing antibody", "novel", "novel vaccines", "pandemic disease", "pandemic virus", "pathogen", "predictive modeling", "pressure", "public health intervention", "recurrent infection", "research and development", "skills", "structural biology", "therapy development", "transfusion medicine", "vaccine candidate", "vaccine development", "variants of concern", "virology" ], "approved": true } }, { "type": "Grant", "id": "15952", "attributes": { "award_id": "1K25AI196259-01", "title": "Modeling SARS-CoV-2 variant emergence from immunocompromised hosts", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32891, "first_name": "MARY KATHERINE BRADFORD", "last_name": "PLIMACK", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-04-02", "end_date": "2031-03-31", "award_amount": 161946, "principal_investigator": { "id": 44397, "first_name": "Katherine", "last_name": "Owens", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3410, "ror": "", "name": "FRED HUTCHINSON CANCER CENTER", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "This proposal describes a five-year research training program that will facilitate my ongoing transition from an applied mathematician to an independent, quantitative, multidisciplinary biomedical researcher. I will work closely with clinicians, mathematical modelers, bioinformaticians, evolutionary biologists, virologists and immunologists to develop a suite of mathematical models which will be validated against viral, immune, phylogenetic and epidemiolocal datasets. The goals of my proposal will be to: 1) understand the mechanisms facilitating generation of SARS-CoV-2 variants of concern (VOC) during prolonged infections in immunocompromised (IC) individuals, and 2) identify key bottle necks that limit the number of VOCs that predominate in the general population. SARS-CoV-2 is the appropriate virus for which to develop this modeling framework due to the availability of data, and ongoing incidence, but the approach will be widely applicable to other pathogens. The training program includes an outstanding group of mentors and collaborators. My scientific advisory committee consists of experts in modeling infectious diseases (Dr Josh Schiffer and Dr Dan Reeves), clinical care for IC individuals (Dr Josh Schiffer and Dr. Alpana Wahgmare), epidemiology (Dr Cheryl Cohen and Dr Dobromir Dimitrov), viral evolution (Dr JT McCrone and Dr Mahan Ghafari), and biostatistics and machine learning (Dr Ollivier Hyrien). This group is dedicated to ensuring the success of my project, and my career development as an independent researcher. The specific learning goals required for my successful transition to biomedical research will be accomplished through didactic coursework in virology, immunology, epidemiology and phylogenetics as well as conferences and professional training in the skills of a successful mentor and group leader. The research plan addresses a critically important clinical and public health issue. Prolonged SARS-CoV- 2 infections in IC individuals are the most likely source of most novel VOC, which have extended and strongly exacerbated the impact of the pandemic. Though these infections have had an outsized public health impact, clear guidance regarding clinical management and safety measures is lacking. Understanding the within-host evolution of SARS-CoV-2 is paramount to addressing these issues. Through accomplishing the aims of this proposal, Dr Owens will address critical gaps in our knowledge of SARS-CoV-2 evolution and create an in silico framework to study SARS-CoV-2 interventions at both individual and population level. Ultimately, this proposal will allow Dr Owens to influence the future of pandemic response research as well as build a self-sustaining program at the interface of mathematical modeling, immunology, viral dynamics, and viral evolution.", "keywords": [ "2019-nCoV", "Address", "Advisory Committees", "Aftercare", "Anatomy", "Award", "Biomedical Research", "Biometry", "COVID-19 impact", "COVID-19 incidence", "Calibration", "Cessation of life", "Clinical", "Clinical Management", "Clinical Trials", "Data", "Data Set", "Dedications", "Effectiveness of Interventions", "Ensure", "Epidemiology", "Evolution", "Frequencies", "General Population", "Generations", "Genetic", "Genetic Drift", "Genetic Recombination", "Goals", "Guidelines", "Health Policy", "Heterogeneity", "Immune", "Immune response", "Immunity", "Immunocompromised Host", "Immunologics", "Immunologist", "Immunology", "Incidence", "Individual", "Infection", "Intervention", "Kinetics", "Knowledge", "Learning", "Link", "Machine Learning", "Mathematics", "Measures", "Mentors", "Mentorship", "Modeling", "Mutate", "Mutation", "Neck", "Nucleotides", "Output", "Pattern", "Phylogenetic Analysis", "Population", "Program Sustainability", "Public Health", "Published Comment", "Recording of previous events", "Research", "Research Personnel", "Research Training", "Risk", "Risk Factors", "SARS-CoV-2 infection", "SARS-CoV-2 variant", "Safety", "Scientist", "Social Distance", "Source", "Testing", "Training", "Training Programs", "United States National Institutes of Health", "Vaccination", "Variant", "Viral", "Viral Genes", "Viral Load result", "Virus", "Virus Replication", "Work", "career", "career development", "chronic infection", "clinical care", "community transmission", "design", "epidemiologic data", "experience", "fitness", "future pandemic", "immunological status", "in silico", "ineffective therapies", "infectious disease model", "insight", "machine learning method", "mathematical model", "multidisciplinary", "novel", "pandemic impact", "pandemic preparedness", "pandemic response", "pathogen", "patient oriented", "pressure", "skills", "success", "symposium", "tool", "transmission process", "vaccine distribution", "variants of concern", "viral rebound", "virology" ], "approved": true } } ], "meta": { "pagination": { "page": 1, "pages": 1424, "count": 14236 } } }